Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Argus Health
US Department of Justice
Boehringer Ingelheim
Fish and Richardson
Farmers Insurance

Generated: October 22, 2017

DrugPatentWatch Database Preview

Details for Patent: 4,237,126

« Back to Dashboard

Summary for Patent: 4,237,126

Title: 2.beta., 16.beta.-bis-piperidino-androstanes
Abstract:New and pharmacologically useful pharmaceutically acceptable acid addition salts are disclosed for the 16.beta.-mono-quaternary ammonium derivatives of either the 2.beta., 16.beta.-bis-piperdino-3-.alpha., 17.beta.-dihydroxy-5.alpha.-androstane 3.alpha., 17.beta.-di-lower aliphatic esters of the 2.beta., 16.beta.-bis-piperidino-3.alpha.-hydroxy-5.alpha.-androstane-3.alpha.-lowe r aliphatic esters, which salts are surprisingly relatively stable in aqueous solutions, so that they provide stable aqueous injection preparations.
Inventor(s): Carlyle; Ian C. (Hamilton, GB6), Sleigh; Thomas (Wishaw, GB6), Savage; David S. (Glasgow, GB6)
Assignee: Akzona Incorporated (Asheville, NC)
Application Number:06/067,878
Patent Claim Types:
see list of patent claims
Compound; Composition;

No matches for this query

Foreign Priority and PCT Information for Patent: 4,237,126

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom35667/78Sep 5, 1978

International Patent Family for Patent: 4,237,126

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina228728► Subscribe
Austria921► Subscribe
Australia526270► Subscribe
Australia5034879► Subscribe
Canada1134813► Subscribe
Germany2962627► Subscribe
Denmark361779► Subscribe
Denmark159119► Subscribe
European Patent Office0008824► Subscribe
Spain483894► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus